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Background: MEF2C is an important regulator of many developmental programs.
Results: Alternative splicing of the  exon of MEF2C regulates myogenesis. Loss of SRPK3 in
rhabdomyosarcoma cells inhibits this splicing and blocks differentiation.
Conclusion: MEF2C2 promotes myogenesis and restoration of MEF2C2 in rhabdomyosarcoma cells
inhibits growth.
Significance: Defining the function and deregulation of MEF2C2 enhances the understanding of
normal myogenesis and RMS tumorigenesis.
ABSTRACT
Rhabdomyosarcoma (RMS) is the most
common soft tissue sarcoma in children. Many
cellular disruptions contribute to the
progression of this pediatric cancer including
aberrant alternative splicing. The MEF2
family of transcription factors regulates many
developmental programs, including
myogenesis. MEF2 gene transcripts are subject
to alternate splicing to generate protein
isoforms with divergent functions. We found
that MEF2C1 was the ubiquitously expressed
isoform which exhibited no myogenic activity
and that MEF2C2, the muscle specific
MEF2C isoform, was required for efficient
differentiation. We showed that exon  in
MEF2C was aberrantly alternatively spliced in
RMS cells, with the ratio of highly
downregulated in RMS cells compared with
normal myoblasts. Compared with MEF2C2,
MEF2C1 more strongly interacted with and

recruited HDAC5 to myogenic gene promoters
to repress muscle specific genes.
Overexpression of the MEF2C2 isoform in
RMS cells increased myogenic activity and
promoted differentiation in RMS cells. We
have also identified a serine protein kinase,
SRPK3, which was downregulated in RMS cells
and found that expression of SRPK3 promoted
the splicing of the MEF2C2 isoform and
induced differentiation. Restoration of either
MEF2C2 or SPRK3 inhibited both
proliferation and anchorage independent
growth of RMS cells. Together, our findings
indicate the alternative splicing of MEF2C
plays an important role in normal myogenesis
and RMS development. Improved
understanding of alternative splicing events in
RMS cells will potentially reveal novel
therapeutic targets for RMS treatment.
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Introduction
The myocyte enhancer factor 2 (MEF2) is
a regulator of many developmental programs,
including myogenesis (1). MEF2 is encoded by
four vertebrate genes which encode MEF2A,
MEF2B, MEF2C and MEF2D. The MEF2 family
is expressed in distinct but overlapping temporal
and spatial expression patterns in the embryo and
adult (2). Both MEF2C and MEF2D are
implicated in myogenesis (3,4), which is
controlled by the concerted activity of the
myogenic regulatory factors (MRFs), a group of
four highly related bHLH transcription factors
composed of Myf5, MyoD, Myf6, and myogenin
(5). MEF2 factors alone do not possess myogenic
activity, but work in combination with the MRFs
to drive the myogenic differentiation program (6).
MEF2 proteins control differentiation,
proliferation, survival and apoptosis in a wide
range of cell types. The N-terminus of the MEF2
proteins contains a highly conserved MADS box
and an immediately adjacent motif termed the
MEF2 domain. Together, these motifs mediate
dimerization, DNA binding and co-factor
interactions (7). The C-terminus of the MEF2
proteins is highly divergent among the family
members and functions as the transcriptional
activation domain. MEF2 proteins function as
endpoints for multiple signaling pathways and
confer a signal-responsiveness to downstream
target genes. MAP kinase pathways are known to
converge on MEF2 (8,9), resulting in a
phosphorylation of the transcriptional activation
domain of MEF2 which augments its
transcriptional activity. Calcium signaling
pathways also modulate MEF2 activity through
multiple mechanisms (10-13). The activity of
MEF2 is tightly controlled by class II HDACs,
which bind to the MADS domain and promote the
formation of multiprotein repressive complexes on
MEF2 dependent genes (14). Phosphorylation of
class II HDACs is mediated by calcium regulated
protein kinases, which promote the nuclearcytoplasmic shuttling of the HDACs and
subsequent activation of MEF2C (14,15).
Each of the MEF2 genes are subject to
extensive alternative splicing. MEF2C contains
three alternative exons: the mutually exclusive
exons 1/2, the skipping/inclusion exon  and
the 3' splice site region . The 1 domain is
expressed ubiquitously, while the 2 domain is

strongly expressed in skeletal muscle (16). The
function of the  domain is unknown, although it
has been shown that isoforms entirely lacking the
 domain have enhanced activity (17). Inclusion
of the  exon has been described in neural cells
(16,18) and the presence of the -exon in MEF2C
was found to strongly activate MEF2C responsive
reporters (19). The  domain, generated by
alternative splice site acceptors, has an inhibitory
effect on the activity of MEF2C and isoforms
lacking this domain better synergize with MyoD
(20). The use of alternative isoforms in skeletal
muscle differentiation has been recently shown
for MEF2D, which promotes late muscle
differentiation through use of alternative isoforms
which generates a muscle specific MEF2D2
isoform (21), which binds to the co-activator
ASH2L and is resistant to phosphorylation by
PKA and association with HDACs (22).
Rhabdomyosarcoma (RMS) is a highly
malignant tumor that is the most common form of
soft tissue tumors in children. It is thought to arise
as a consequence of myogenic precursors failing
to differentiate into normal muscle (23). There
are two major histological categories of RMS, the
embryonal (ERMS) and alveolar (ARMS)
subtypes. The more common form of the disease
is the ERMS subtype. ARMS, the more
aggressive form of RMS, is characterized by
chimeric transcripts that fuse the 5’ DNA binding
domain of PAX3 or PAX7, respectively, to the
transactivation domain of a forkhead transcription
factor, creating novel PAX3/7-FOXO1 fusion
proteins (24,25).
Rhabdomyosarcoma tumors express the
myogenic regulatory factors, but the MRFs are
unable to promote differentiation (26). Indeed,
MyoD and myogenin are used as diagnostic
markers for RMS as they are expressed in almost
every RMS tumor including both major
histological subtypes, embryonal RMS (ERMS)
and alveolar RMS (ARMS) (27). Many blocks to
differentiation have been described and were the
subject of a recent review (26). Exogenous
expression of MEF2C (28) or MEF2D (29) can
promote differentiation in RMS cells.
We have shown that the muscle specific
MEF2C isoform (MEF2C2) was required for
efficient differentiation of skeletal muscle cells
and that this isoform was highly downregulated in
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RMS cells. MEF2C isoforms containing the 2
exon have potent myogenic activity as assayed by
muscle specific gene reporters, muscle specific
gene expression and myotube formation, while
isoforms containing 1 or lacking the domain
did not. Despite the robust expression of
MEF2C1 in RMS cells, restoration of the
MEF2C2 isoform promoted RMS differentiation
and myotube formation. The MEF2C1 isoform
had an enhanced association with HDAC5, which
resulted in enhanced recruitment of class II
HDACs to target promoters in the presence of
MEF2C1. We found that the alterative splicing
of the 1/2 exon of MEF2C was controlled by
the protein kinase SRPK3, which is specific for
the SR (serine/arginine-rich domain) family of
transcription factors, including the splicing factor
ASF. We showed that SRPK3 was downregulated
in RMS cells. Exogenous expression of SRPK3 in
RMS promoted the splicing of the MEF2C2
isoform, induced expression of muscle specific
genes and drove the formation of myotubes.
Exogenous expression of MEF2C2 or SRPK3
inhibited the proliferation and anchorage
independent growth of RMS cells.
Experimental procedures
Cell Culture
RD (ATCC), SJRH30 (RH30) cells (ATCC),
C2C12 myoblasts (ATCC), 10T1/2 cells (ATCC)
and HEK293 cells (ATCC) were grown in
Dulbecco's modified Eagle medium (DMEM)
supplemented with 10% fetal bovine serum
(Hyclone) according to standard protocols. To
induce differentiation of C2C12 myoblasts into
myotubes, cells were grown to 70% confluence
and the media switched to DMEM supplemented
with 2% horse serum (Hyclone). C2C12 cells
were grown in differentiation medium for the
number of days indicated in each experiment.
Cloning
Murine Mef2C2 (mMef2C2) and Srpk3 were
PCR amplified from cDNA reverse transcribed
from RNA isolated from C2C12 cells
differentiated for four days. Human MEF2C
isoforms (hMEF2C) were PCR amplified from
cDNA generated from RNA isolated from human
myoblasts (gift of Denis Guttridge, Ohio State
University), RH30 cells or HEK293 cells. A

common primer set, MEF2C TOPO F 5'
ATGGGGAGAAAAAAGATTCAGA 3' and
MEF2C TOPO R 5'
TCATGTTGCCCATCCTTCA 3', was used to
amplify both mMef2C and hMEF2C. Each of the
PCR amplified fragments were cloned into the
pEF6/V5 His TOPO TA expression vector and the
clones confirmed by sequencing.
Western Blot Analysis
Cell extracts were made by lysing PBS
washed cell pellets in radio-immunoprecipitation assay
buffer (RIPA) supplemented with protease inhibitors
(Complete protease inhibitor, Roche Diagnostics).
Following incubation on ice, clear lysates were
obtained by centrifugation. Protein concentrations
were determined by Bradford’s assay (Bio-Rad). For
each sample, 30 µg of protein was loaded on each gel.
Proteins were transferred onto a PVDF membrane
using a tank blotter (Bio-Rad). The membranes were
then blocked with 5% milk in 1X Tris buffered saline
plus Tween 20 (TBST) and incubated with primary
antibody overnight at 4ºC. Membranes were then
washed with 1X TBST before incubation with the
corresponding secondary antibody. Membranes were
washed again with 1X TBST, incubated with
chemiluminescent substrate according to
manufacturer's protocol (SuperSignal, Pierce) and
visualized by autoradiography. The antibodies used
include anti- MEF2C (D80C1, Cell Signaling), antiHDAC5 (Cell Signaling), anti-V5 (Rockland), antiMHC (MF-20, Developmental Studies Hybridoma
Bank) and anti-GAPDH (Millipore).
Gene expression analysis
RNA was isolated from cells by Trizol
extractions (Invitrogen). Following treatment with
DNase (Promega), two micrograms of total RNA
was reversed transcribed with MultiScribe™
MuLV reverse transcriptase (Applied Biosystems).
cDNA equivalent to 40 ng was used for
quantitative polymerase chain reaction (qPCR)
amplification (Applied Biosystems) with SYBR
green PCR master mix (Applied Biosystems).
Samples in which no reverse transcriptase was
added (no RT) were included for each RNA
sample. The relative levels of expression of genes
were normalized according to those of
hypoxanthine guanine phosphoribosyl transferase
(HPRT) qPCR data were calculated using the
comparative Ct method (Applied Biosystems).
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Standard deviations from the mean of the [Δ] Ct
values were calculated from three independent
RNA samples. Primers corresponding to the
indicated genes were as described (30). Where
possible, intron spanning primers were used. All
quantitative PCR was performed in triplicate and
three independent RNA samples were assayed for
each time point. For measurements of relative
gene expression (fold change), a fold change was
calculated for each sample pair by dividing the
mRNA expression values of each sample pair.
Each experimental fold change was then
normalized to the fold change observed at HPRT.
Chromatin immunoprecipitation
ChIP assays were performed and
quantified as described previously (31) with the
following modifications: 1x107 cells were used for
each immunoprecipitation and protein A agarose
beads (Invitrogen) were used to
immunoprecipitate the antibody:antigen
complexes. The following antibodies were used:
HDAC5 (Cell Signaling), HDAC4 (Cell
Signaling) and rabbit IgG (Santa Cruz
Biotechnology) as a non-specific control. Primers
corresponding to the LMOD2 and CDKN1A
promoters were as described (32). The real time
PCR was performed in triplicate. Values of [Δ]
[Δ] Ct were calculated using the following formula
based on the comparative Ct method: Ct, template
(antibody) - Ct, template (IgG) = [Δ] Ct. Fold
enrichments were determined using the formula : 2
- [Δ] Ct.
(experimental)/2 -[Δ] Ct (reference, CHR19).
Standard error from the mean was calculated from
replicate [Δ][Δ] Ct values obtained from at least
three individual experiments.
Cell Transfections and Luciferase Assays
Cells were transfected with calcium
phosphate according to standard protocols. The
plasmids pEF6-mMef2C2, -, +, pEF6hMEF2C1, -, +, pEF6-hMEF2C1, -, -,
pEF6-hMEF2C2, -, - , pEF6-hMEF2C2, -,
+, and pEF6-hMEF2C-,-, + were used for
expressing different isoforms of mMef2C and
hMEF2C. pEF6-SRPK3 was used to express
SRPK3. The plasmid pEMCIIs (provided by
Andrew Lassar, Harvard Medical School) was
used for expressing MyoD. Luciferase activity
was determined using the Dual-Luciferase

Reporter Assay System (Promega). RH30 or RD
cells were seeded at a density of 5x103 cell per
well in 96 well plates and transfected with 0.4 ug
of DNA. Transfections were normalized to
Renilla luciferase. Transfections were performed
in triplicate and all data sets were repeated at least
twice.
Stable Cell Lines
Stable C2C12, RD and RH30 cell lines
overexpressing exogenous MEF2C or SRPK3 were
constructed by transfecting cells with linearized pEFV5 His vector (empty vector), linearized pEF-MEF2C
or linearized pEF-SRPK3 and selecting for blasticidin
(10 ug/ml) resistant colonies. Murine clones of
Mef2C1 and Mef2C2 were used in murine cell lines
and human clones were used in human cell lines.
Individual clones were isolated and propagated.
Immunohistochemistry
Cells were grown on cover slips, fixed
with paraformaldehyde, incubated with goat serum
supplemented with 1.0 % NP-40 for one hour and
washed with PBS. Primary antibodies against
myosin heavy chain (1:100, MF20, Developmental
Studies Hybridoma Bank) were incubated for 2
hours at room temperature, washed with PBS and
detected by Alexa Fluor-488 goat anti-mouse
antibody (1:500, Invitrogen). Cell nuclei were
then stained by incubating with DAPI (1 M,
Invitrogen) for 5 min.
Proliferation
Cells were seeded in a six well plate at
6x104 per well and harvested every two days for
cell counts with a hemocytometer. All counts
were performed in triplicate and individual
experiments repeated three times.
Soft agar assay
Soft agar assays were carried out in 60
mm dishes in which 2 ml of 0.7% Noble agar
(USB) in 1X DMEM with 10% FBS was overlaid
with 2 ml of 0.35% agar in 1X DMEM with 10%
FBS containing 3x105 cells. RD and RH30 cells
transected with pEF6 V5 His(vector), MEF2C2
and SRPK3 were grown to 70% confluence,
trypsinized, and dispersed. Cells of each clone
were plated in triplicate. 1 ml of culture medium
was added to the top of each plate every 5 days
and cells were grown at 37oC for 30 days. The
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plates were stained with 1 ml of 0.05% Crystal
Violet (Fisher) for > 1 hour and colonies were
counted using a dissecting microscope.
Statistics
qPCR data are presented as means ± standard
deviation (SD). Statistical comparisons were
performed using unpaired two-tailed Student's t tests,
with a probability value of <0.05 taken to indicate
significance.
Results
The muscle specific 2 exon of MEF2C is not
expressed in RMS cells
To understand the blocks to differentiation
in RMS cells, we undertook an analysis of the
MEF2 family in RMS. During the course of this
work, we found that both RD and RH30 cells
highly expressed MEF2C (29), although MEF2C
has also been reported to be downregulated in RD
cells (28). MEF2C has been shown to play an
important role in myogenesis and MEF2C is
subject to alternative splicing by
exclusion/inclusion of exon α1/2, exon β and exon
γ (Figure 1A). The exon β has been reported to
enhance MEF2C activity, while exon γ plays an
inhibitory role. However, the function of the
mutually exclusive exons α1/α2 has not yet been
characterized. To characterize the function of the
MEF2C isoforms, we cloned MEF2C from RH30
cells, human myoblasts, C2C12 cells and HEK293
cells. The isoforms recovered from each cell type
are shown in Figure 1B. As has been previously
observed (16), the muscle specific2 exon was
only found in mRNA from C2C12 cells and
human myoblasts. The transcripts from C2C12
cells each contained the inhibitory  domain, while
human myoblast RNA produced transcripts with
or without the  domain. Both RD and RH30 cells
contained the 1 exon with or without the gamma
( domain. HEK293 cells expressed isoforms
either with the 1 domain or lacking the  domain
entirely. The transcripts containing the 1 domain
lacked the  domain, and the transcripts without
the  domain contained the  domain. Consistent
with the prior analyses which identified the  exon
exclusively in neuronal tissue (16,18), we
identified no transcripts which contained the 
domain from any of the cell types in our study.
We sought to verify our results using
reverse transcription PCR (RT-PCR) to detect the

expression of exon α and exon β by exon specific
primers in normal muscle and RMS cells. The
location of the primers is shown in Figure 2A.
Consistent with the results shown in Figure 1, we
found that the MEF2C1 exon was ubiquitously
expressed in both proliferating and differentiated
C2C12 cells, human myoblasts and the RMS cell
lines (Figure 2B). The MEF2C2 exon was only
expressed in differentiated C2C12 cells and human
myoblasts (Figure 2B). Expression of the exon
could not be detected in any of the samples tested
here (Figure 2C). To verify detection of the 
exon, we also assayed samples from the brain,
induced pluripotent stem (iPS) cells and neural
progenitor cells (NPC) derived from iPS cells (33).
As anticipated, we found that brain and NPC cells
expressed the  exon, while iPS cells did not
(Figure 2C).
To further clarify our results, we used
quantitative RT-PCR (qRT-PCR) to quantitate the
expression pattern of MEF2C1/2 isoforms
during normal myogenesis and in RMS cells.
Using primers specific to the1 or 2 domain of
MEF2C, we examined expression in C2C12 cells
throughout a time course of differentiation. We
found that the transcript for MEF2C1 was
expressed in proliferating C2C12 cells (UD) and
expression did not change significantly when cells
were differentiated (Figure 2D). In RMS cells,
expression of MEF2C1 was compared to the
expression levels found in human myoblast RNA.
We found that both RD and RH30 cells expressed
very high transcript levels of MEF2C1 (Figure
2E). When the expression of MEFC2 was
examined, the expression was very low in
proliferating C2C12 cells, but the ratio of 2
expression vs 1 expression sharply increased
upon differentiation (Figure 2F). For RMS cells,
very low expression of MEF2C2 was observed
compared to the expression observed in human
myoblast RNA and the ratio of 2/1 expression
did not increase significantly upon differentiation
(Figure 2G).
MEF2C2 has myogenic activity while MEF2C1
does not.
We next compared the myogenic activity
of the MEF2C isoforms on a muscle specific
reporter. We chose a muscle specific reporter
which contains the Leiomodin2 (Lmod2) promoter
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fused to luciferase, Lmod2-luc, which we have
used previously to characterize the activity of the
MRFs and MEF2D (29,34). The Lmod2-luc
reporter shows very low activity in proliferating
cells and is strongly upregulated upon
differentiation. Transfection of MyoD or
myogenin activate the reporter. Thus, we assayed
for the activity of the Lmod2-luc reporter with
MyoD alone, and in combination with each of the
MEF2 isoforms in 10T1/2 cells, a fibroblast cell
line considered poised for activation of muscle
specific genes. We found that MEF2C1 did not
enhance the activity of the reporter and in fact had
a mild inhibitory effect (Figure 3A). The addition
of the  domain was also modestly inhibitory, as
has been previously seen. The isoform lacking the
 domain did not significantly inhibit or activate
the Lmod2-luc reporter. The MEF2C2 isoform
strongly activated the Lmod2-luc reporter.
Addition of the  domain again lead to a modest
inhibition, but the  domain containing isoform
still robustly activated the Lmod2-luc reporter.
The work indicates that transcripts including 2
are required for MEF2C myogenic enhancing
activity, among which the isoform without 
domain is a modestly stronger than that with 
domain. Transcripts with the 1 exon appear to
inhibit the myogenic activity of MyoD.
To confirm these results, we next assayed
for the activity of the MEF2C isoforms on
endogenous gene expression. 10T1/2 cells were
tranfected with constructs expressing MyoD in
combination with constructs expressing either
MEF2C1 or MEF2C2. Gene expression
analysis confirmed the expression of each MEF2C
isoform (Figure 3B). We found that transfection
of MEF2C2 with MyoD strongly induced muscle
specific gene expression, including myosin light
chain, phosphorylatable, fast (Mylpf), creatine
kinase, muscle (Ckm) and troponin T, type 1
(Tnnt1), while MEF2C1 had no activity (Figure
3C).
Our data are consistent with previous
findings which show that muscle expresses both
MEF2C2 and MEF2C1 (16,18). To determine
the effect of each isoform in muscle, MEF2C1
and MEF2C2 were individually ectopically
expressed in C2C12 cells. Proliferating C2C12
cells were transfected with plasmids expressing
MEF2C1 or MEF2C2 and then induced to

differentiate. Expression of the individual
isoforms was confirmed by qRT-PCR (Figure 4A).
Expression of the exogenous epitope tagged
MEF2C isoforms was also confirmed by western
blot analysis (Figure 4B). When differentiation
specific gene expression was examined, we found
that exogenous expression of MEF2C2
stimulated the expression of actin (Acta1),
troponin 1 type 2 (Tnni2) and leiomodin 2
(Lmod2), while the MEF2C1 isoform had a
modest inhibitory effect (Figure 4C). The effect
on differentiation was also assayed by
immunostaining for expression of myosin heavy
chain (MHC), which is commonly used as a
marker for myogenesis. We found that ectopic
expression of MEF2C2 significantly stimulated
the formation of myosin heavy chain positive
myotubes, while the expression of MEF2C1 was
inhibitory for myotube formation (Figure 4D).
To determine if MEF2C2 could rescue
the MRF dependent activation of muscle specific
genes in RMS, we first asked if MEF2C2 could
activate the Lmod2 reporter in RD cells. We
found that MEF2C2 robustly induced the Lmod2
reporter, while the MEF2C1 isoform was not
able to activate the reporter (Figure 5A).
Consistent with our results in Figure 3, we found
that MEF2C2 robustly stimulated the Lmod-luc
reporter in RD cells. The isoform lacking an 
domain did modestly activate the reporter (~2
fold), but not nearly to the degree as the
MEF2C2 isoform. Next, we examined the effect
on the expression of differentiation specific genes
in RD cells and found that MEF2C2 stimulated
the expression of LMOD2, TNNI2 and CDKN1A
(p21) (Figure 5B). The cell cycle regulator p21 is
required for terminal differentiation (35) and is
regulated in part by MyoD in muscle (36). To
determine if the MEF2C2 isoform could promote
differentiation in RMS cells, exogenous
MEF2C1 and MEF2C2 were expressed in RD
cells and myotube formation assayed by myosin
heavy chain (MHC) immunohistochemistry. We
found that MEF2C2 expression markedly
induced differentiation in RD cells (Figure 5C).
MEF2C1 preferentially associates with HDAC5
To begin to address how the 2 exon of
MEF2C promotes myogenesis while the 1 exon
does not, we asked if the association with histone
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deacetylases (HDACs) with each isoform was
distinct. MEF2 is well known to interact with
histone deacetylases (1), and the differential
phosphorylation of the 1/2 exon of MEF2D
alters the association with HDACs (22). Thus, we
asked if a difference in HDAC association could
be observed for MEF2C1 vs MEF2C2.
HEK293 cells, which express endogenous
MEF2C1, were transfected with constructs
expressing MEF2C1 or MEF2C2. MEF2C
proteins were immunoprecipitated with antibodies
against MEF2C and the immunoprecipitate probed
for HDAC5. We found that the cells transfected
with a plasmid expressing MEF2C2
immunoprecipitated HDAC5 less robustly than
cells transfected with a plasmid expressing
MEF2C1 (Figure 6A). The antibody used for the
immunoprecipitation could immunoprecipitate
both MEF2C1 and MEF2C2, so it is possible
that the differential association of HDAC5 might
be more significant than that indicated by our
experiment as HEK293 cells have endogenous
levels of MEF2C1. Selective
immunoprecipitation of the isoforms using epitope
tags on the constructs was attempted, but nonspecific bands in the immunoprecipitate precluded
analysis of HDAC association.
To understand if the differential
association of HDAC5 observed would influence
HDAC recruitment to target genes, we performed
chromatin immunoprecipitation (ChIP) assays for
HDAC5 in RD cells, which express MEF2C1,
transfected with a vector control or with a
construct expressing exogenous MEF2C2. We
found that HDAC5 could be detected on muscle
specific promoters in RD cells transfected with
vector, but this association was decreased when
MEF2C2 was expressed (Figure 6B). The
decrease in HDAC recruitment was also observed
at the CDKN1A (p21) promoter. We also
examined the recruitment of HDAC4, an
additional class II HDAC, by ChIP assays and
found that HDAC4 association was also disrupted
by MEF2C2 expression (Figure 6C). Our data
indicate that MEF2C2 may promote muscle gene
expression at least in part by reducing the
recruitment of HDACs to target promoters and
thus promoting gene activation.
SRPK3 is downregulated in RMS cells

As our data suggested that the lack of
expression of MEF2C2 in RMS cells might
contribute to the block to differentiation in these
cells, we sought to understand why the MEF2C2
isoform was not expressed in RMS cells. To
address this, we attempted to identify the splicing
factors which controlled the  isoform selection.
Two bioinformatic databases, Expasy (37) and
Uniprot (38), were used to predict the splicing
factors which might recognize the  exon splice
sites in MEF2C. Both programs predicted the
serine/arginine-rich splicing factor 1, SRSF1
(ASF), which is activated by phosphorylation. To
initiate our analysis, we assayed for the expression
of ASF in skeletal muscle and RMS cells. We
found that the expression of ASF is modestly
upregulated during myogenesis (Figure 7A),
consistent with a role for promoting the MEF2C1
to MEF2C2 switch. However, when RMS cells
were analyzed for expression of ASF, we found
that ASF was highly upregulated compared to
human myoblasts (Figure 7B). This result is
consistent with many other studies which show
that ASF is often highly upregulated in cancer
(39).
We next looked for expression of
upstream kinases required for activation of ASF.
We choose SRPK3, a muscle specific protein
kinase which is regulated by MEF2C in skeletal
muscle (40). As has been previously shown (40),
SRPK3 was strongly upregulated during normal
myogenesis (Figure 7C). We also found that
SRPK3 was downregulated in RMS cells (Figure
7D). To determine if SRPK3 was required for
splicing of the MEF2C2 isoform, SRPK3 was
depleted from C2C12 cells using shRNA
constructs. Multiple shRNA constructs were used
independently and the results of two individual
constructs are shown. We found that the
constructs depleted SRPK3 (Figure 7E) and
inhibited splicing of the MEF2C2 isoform when
assayed after two days of differentiation (Figure
7F).
SRPK3 activates the splicing of MEF2C2 and
promotes differentiation in RMS cells
To determine if the downregulation of
SRPK3 contributed to the isoform selection in
MEF2C and the block to differentiation in RMS
cells, we ectopically expressed SRPK3 in RD
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cells. The expression of SRPK3 was confirmed by
qRT-PCR (Figure 8A). The expression of the
MEF2C1 and MEF2C2 isoforms was then
analyzed and we found that expression of
exogenous SRPK3 did not significantly alter the
expression of the MEF2C1 isoform, but did
strongly enhance expression of the MEF2C2
isoform (Figure 8B). To determine if the
expression of SRPK3 could promote
differentiation, we assayed these cells for
differentiation specific gene expression including
LMOD2, ACTA1, TNNT1 and CDKN1A. We
found that each of these genes were upregulated in
cells expressing SRPK3 (Figure 8C), strongly
suggesting the SRPK3 promotes differentiation
specific splicing which allows expression of the
appropriate transcripts required for differentiation.
Differentiation was also assayed by
immunostaining for MHC in RD cells transfected
with expression constructs for vector, MEF2C2
or SRPK3. We found that MEF2C2 or SRPK3
promoted robust MHC signal and the appearance
of myotubes (Figure 8D). To determine if SRPK3
and MEF2C2 could also promote differentiation
in ARMS cells, the above experiment was
repeated in RH30 cells and again, robust
expression of MHC was observed (Figure 8D).
Finally, we sought to understand if
SRPK3 or MEF2C2 could inhibit the
proliferation and tumorigenic growth of RMS
cells. RD cells expressing exogenous SRPK3 or
MEF2C2 were assayed for proliferation and we
found these cells had reduced proliferation rates
when compared to the vector only controls (Figure
9A). To extend this result to the ARMS subtype
of RMS, the proliferation assay was repeated in
RH30 cells. We found that exogenous expression
of SRPK3 or MEF2C2 also inhibited the
proliferation of RH30 cells (Figure 9B). To
determine if SRPK3 or MEF2C2 could inhibit
anchorage independent growth of these cells,
growth in soft agar media was assayed. We found
that RD cells expressing exogenous MEF2C2 or
SRPK3 formed fewer colonies in soft agar media
(Figure 9C) and the colonies which did form were
smaller in size than that observed for the vector
only controls (Figure 9D). The data suggest that
restoration of differentiation specific splicing may
inhibit RMS tumor growth.
Discussion

We show here that the 2 exon of MEF2C
confers myogenic activity on MEF2C and results
in differential HDAC recruitment to target
promoters. The expression of the MEF2C1 exon
in RMS cells contributes to the lack of
differentiation observed in those cells. The
splicing of the 2 exon is promoted by SRPK3
and restoration of SRPK3 or MEF2C2 in RMS
cells enhances differentiation and inhibits
proliferation and tumorigenic growth. MEF2C has
been previously shown to induce differentiation in
RMS cells (28) and our results reveal that the
deficiency in MEF2C activity is due to the lack of
appropriate muscle specific splicing.
Defects in alternative splicing have been
previously observed in RMS cells. The oncogenes
Murine Double Minute 2 (MDM2) and MDM4
exhibit genotoxic-stress inducible splice forms in
high risk metastatic disease represented by both
ERMS and ARMS. Expression of these alterative
isoforms promotes metastatic behavior of tumor
cells (41). Multiple splicing isoforms of PAX3,
PAX7 and the PAX-FOXO1 fusions have also
been observed in RMS and differences in the
PAX7 splicing pattern between murine skeletal
muscle and RMS tumors has been observed (42).
To our knowledge, our work is the first to
implicate the deregulation of a splicing factor in
RMS. We show here that SRPK3 is required for
the isoform switch between MEF2C1 and
MEF2C2, but likely controls the splicing of
many other genes required for normal muscle
differentiation.
A recent study has shown that the
expression and alternative splicing of the MEF2
genes are deregulated in muscle from
neuromuscular disorder (NMD) patients, including
DM1 and DM2 (43). In DM, expression of a 224
bp isoform encompassing exons 4A and 4B
(corresponding to MEF2C1) was found to
expressed in muscle while normal muscle
contained a 217 bp isoform encompassing exon 5a
(corresponding to MEF2C2) (43). Our work
suggests that expression of MEF2C1 in diseased
muscle would prevent appropriate differentiation
specific gene expression and contribute to the
muscle dysfunction observed in the patients.
In a related study, MEF2C was found to
be deregulated in cardiac tissue of DM1 patients
(44). A screen of microRNAs revealed that
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several miRNAs were differentially expressed in a
mouse model of DM1, and many of these miRNAs
were direct MEF2 transcriptional targets. A down
regulation of MEF2C and MEF2A was observed
in both the mouse models and in human DM1
cardiac tissues and restoration of MEF2C
promoted expression of miRNA and mRNA
targets in DM1. Cardiac tissue is thought to
express the1 isoform of MEF2C and it will be
interesting to understand how alternative splicing
of MEF2C contributes to the dysfunction of
MEF2C observed in both cardiac and skeletal
muscle tissue in DM1 patients.
It is intriguing that the MEF2D2 isoform
has been recently shown activate differentiation
specific transcription (22), while the ubiquitously
expressed MEF2D1 form does not, similar to
what we observed with MEF2C. In the case of
MEF2D, the activity was shown to be due to
differential phosphorylation of the 1 vs 2 exon
mediated by PKA (22,45). Phosphorylation of the
MEF2D1 isoform induces association with
histone deacetylases (22). We also see that the 1
exon of MEF2C interacts preferentially with
HDAC5 and induces the recruitment of HDAC5
and HDAC4 to target promoters. The basis of the
differentiation interaction with HDAC5 is
currently unclear for MEF2C, but it may also
involve differential phosphorylation. The
phosphorylation of MEF2C is unlikely to be
mediated by PKA as MEF2C has been reported to
be a poor substrate for PKA (45) and the 1 exon
of MEF2C does not contain consensus sites for
PKA phosphorylation.
Besides the modulation of MEF2C by
HDACs, we cannot rule out the potential
regulation of 1/2 through differential
interactions with other transcription factors and
co-factors. Many factors have been shown to
modulate the activity of MEF2C during
myogenesis including the myogenic regulatory
factors, MyoD and myogenin (46); the histone
acetyltransferase, P300 (47); the steroid nuclear
receptor coactivator NCOA2/GRIP-1 (48) and
mastermind-like transcriptional coactivator
(MAML) (49). The calcineurin inhibitor Cabin1
sequesters MEF2C in a transcriptionally inactive
state which is released by an increase in
intracellular calcium concentration (50). The
differential interaction of MEF2Cα1 and

MEF2Cα2 with any of these factors may
contribute to the differences in myogenic activity
we observe here. Intriguingly, the MEF2C1
domain has previously been shown to the target of
the inhibitory effect of the Notch signaling
pathway, which represses myogenesis (51). The
SVGHSPESEDKY region, which is uniquely
present in MEF2Cα1 and not in MEF2Cα2,
MEF2A, MEF2B or MEF2D, was shown to be
required for the Notch mediated repression.
Activated Notch signaling is common in many
cancers and activated Notch has also been
observed in RMS cells (52). Thus, differential
interactions of the MEF2C 1/2 isoforms with
the Notch signaling pathway may also contribute
to the differential activity of the isoforms. The
data shown here confirm that MEF2C constructs
entirely lacking the domain have higher activity
than the MEF2C1 isoform found in RMS cells.
Further understanding of how elevated Notch
signaling and MEF2C1 expression in RMS cells
may contribute to the pathology of RMS is an
important future direction for these studies.
MEF2C is a direct transcriptional activator
of many important developmental genes including
c-jun (53) and matrix metalloproteinase 10
(MMP10) (54). MEF2C is also a direct
transcriptional activator of several miRNAs
including miR-1, miR-21, miR-29, miR-30, miR133 (44). It will be important to understand which
isoform of MEF2C directs transcription of these
important targets in each system and how the
differential expression and regulation of the
isoforms contributes to appropriate expression of
MEF2C target genes.
While the MEF2C2 isoform was known
to be expressed in skeletal muscle, our results
reveal the requirement for the 2 exon for
myogenesis and show that the differentiation
defect in RMS cells extends to the muscle specific
splicing patterns required for differentiation. It
will be important to further understand the
deregulation of splicing factors such as SRPK3 in
RMS as targeting these changes may offer novel
therapeutic approaches for treating RMS.
Defining the molecular basis for the myogenic
activity of the2 exon of MEF2C and the
differential recruitment of HDAC5 will also be
important in understanding normal skeletal muscle
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differentiation. Understanding the function of
the exon of MEF2C and how the appropriate
splicing is achieved also contributes to the
understanding of muscle dysfunction in
neuromuscular disease patients and may
potentially offer new therapeutic approaches for
this disease as well.
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Figure legends
Figure 1. MEF2C isoforms in muscle and RMS. A. A schematic of the MEF2C isoforms is
shown. The sequences of the exons are indicated below. Murine and human sequences are
indicated by m and h, respectively. Amino acids which differ among the species are indicated in
red. B. MEF2C isoforms identified in indicated cell lines. The number beside each isoform
indicates the number of individual isoform clones identified/total number of clones recovered.
Figure 2. Expression of the  and  exons of MEF2C in normal muscle and RMS. A.
Schematic of the exon structure of MEF2C with the location of the primers used to detect the
exons indicated. B. The 1 exon of MEF2C is expressed ubiquitously in skeletal muscle, but
the 2 exon is strongly upregulated during differentiation. Exon expression was detected by RTPCR on the indicated samples. Undifferentiated myoblasts are represented by UD and D
represents the days of differentiation. Human myoblasts are represented by h.m. C. The  exon
is not expressed in muscle or RMS cells. Exon expression was detected by RT-PCR on the
samples indicated as in B. and from induced pluripotent stem (iPS) cells, neural progenitor cells
(NPC) and brain. D. Expression of the1 exon does not change during myoblast differentiation.
Gene expression was assayed by qRT-PCR. Error bars, SD. ***P<0.001. E. The 1 exon is
13

highly expressed in RMS cells as assayed as in D. F. The 2 exon is upregulated during
differentiation as assayed as in D. Data are shown as the ratio of 2 expression relative to the
expression of 1. G. The2 exon is highly down regulated in RMS and not induced by
differentiation as assayed as in F.
Figure 3. MEF2C2 robustly enhances MRF activity, while MEF2C1 does not. A.
MEF2C2 stimulates the activity of MyoD on a muscle specific luciferase reporter construct.
10T1/2 cells were transfected with the indicated constructs. Values are represented with respect
to a luciferase vector with no promoter (pGL3 basic). pGL3 (+) represents a luciferase vector
with the constitutive CMV promoter. Lmod2-luc represents a luciferase vector with a ~300 bp
Leiomodin 2 (Lmod2) promoter. Error bars, SD. ***P<0.001, **P<0.01. B. Confirmation of
the expression of MEF2C1 and MEF2C2. 10T1/2 cells were transfected with expression
constructs for MyoD, MEF2C1 and MEF2C2 as indicated and gene expression was
determined by qRT-PCR for the indicated genes. Vector represents a vector only transfection
where the expression level was set to 1. Error bars, SD. ***P<0.001. C. MEF2C2 activates
endogenous MRF target gene expression. 10T1/2 cells were transfected with expression
constructs for MyoD, MEF2C1 and MEF2C2 and analyzed for the indicated genes as in B.
Figure 4. MEF2C2 promotes myogenesis in C2C12 cells. A. C2C12 cells were transfected
with constructs expressing vector, MEF2C1 or MEF2C2. Expression of the isoforms was
confirmed by qRT-PCR. Error bars, SD. ***P<0.001. B. Protein expression of the epitope
tagged MEF2C isoforms was confirmed by western blot analysis. C. Differentiation specific
gene expression is induced by overexpression of MEF2C2. Gene expression was assayed for
the indicated genes by qRT-PCR. Error bars, SD. ***P<0.001. D. Over expression of
MEF2C2 promotes myotube formation while MEF2C1 is inhibitory. Cell lines in A. were
differentiated for 3 days and immunostained with antibodies against MHC and counterstained
with DAPI. Images were taken at 200X magnification and scale bars represent 5 ms. The data
are quantitated in the lower panel.
Figure 5. MEF2C2 promotes differentiation in RMS cells. A. MEF2C2 activates a muscle
specific reporter in RMS cells. RD cells were transfected with the indicated constructs. Values
are represented with respect to a luciferase vector with no promoter (pGL3 basic). pGL3 (+)
represents a luciferase vector with the constitutive CMV promoter. Lmod2-luc represents a
luciferase vector with a ~300 bp Leiomodin 2 (Lmod2) promoter. Error bars, SD. ***P<0.001.
B. MEF2C2 promotes differentiation specific gene expression in RD cells. RD cells were
transfected with constructs expressing vector, MEF2C1 and MEF2C2. Gene expression was
assayed for the indicated genes by qRT-PCR. Error bars, SD. ***P<0.001. C. MEF2C2
promotes the expression of MHC in RD cells. RD cells expressing vector, MEF2C1 and
MEF2C2 were immunostained for MHC and counterstained with DAPI. Images were taken at
100X magnification and scale bars represent 10 ms.
Figure 6. MEF2C1 recruits HDACs to target promoters. A. MEF2C1 interacts with HDAC5
more robustly than MEF2C2. HEK293 cells were transfected with expression constructs for
MEF2C1 and MEF2C2, immunoprecipitated with an antibody against MEF2C and the blot
probed with antibodies against HDAC5. B. MEF2C2 inhibits recruitment of HDAC5 to target
14

promoters. ChIP assays were performed on RD cells transfected with vector control or an
expression construct for MEF2C2 with antibodies against HDAC5 and immunoprecipitated
DNA probed with primers corresponding to the indicated promoters. Error bars, S.D.
***P<0.001. C. HDAC4 recruitment to target promoters is also inhibited by MEF2C2. ChIP
assays were performed as in B. except with antibodies against HDAC4.
Figure 7. Expression of splicing factors in skeletal muscle and RMS. A. ASF is modestly
upregulated upon differentiation in C2C12 cells. Gene expression was assayed by qRT-PCR and
the days of differentiation are indicated. Error bars, S.D. B. ASF is highly expressed in RMS
cells. Expression was assayed as in A. C. SRPK3 is robustly upregulated upon differentiation
of C2C12 cells as assayed as in A. D. SRPK3 is highly downregulated in RMS cells as assayed
as in A. ***P<0.001. E. Depletion of SRPK3. C2C12 cells were transfected individually with
multiple shRNA contructs (shSRPK3) and stable transformants selected. The two constructs
shown are represented by (1) and (2). Gene expression was assayed after two days of
differentiation by qRT-PCR. Error bars, S.D. ***P<0.001. F. SRPK3 is required for
MEF2C2 splicing. Gene expression was assayed on the shSRPK3 depletions as in E.
Figure 8. SRPK3 and MEF2C2 promote differentiation of RMS cells. A. SRPK3
overexpression in RD cells. RD cells were transfected with a vector control or an expression
construct for SRPK3 and assayed for gene expression by qRT-PCR. B. SRPK3 induces the
expression of MEF2C2. Gene expression was assayed by qRT-PCR. Error bars, S.D.
***P<0.001. C. SRPK3 induces differentiation specific gene expression in RD cells. Cells as
in A. were assayed for gene expression by qRT-PCR for the indicated genes. Error bars, S.D.
***P<0.001. D. SRPK3 or MEF2C2 induce MHC expression in RMS cells. RD (left panel)
and RH30 cells (right panel) were transfected with a vector control or expression constructs for
SRPK3 or MEF2C2 and immunostained for MHC and counterstained with DAPI. Images were
taken at 100X magnification and scale bars represent 10 ms.
Figure 9. SRPK3 and MEF2C2 inhibit growth of RMS cells. A. SRPK3 or MEF2C2 inhibit
the proliferation of RD cells. RD expressing the indicated constructs were seeded at equivalent
densities and harvested for cell counts every two days. Error bars, SD. B. SRPK3 or MEF2C2
inhibit the proliferation of RH30 cells. Proliferation was assayed as in A. C. SRPK3 or
MEF2C2 inhibit the number of anchorage independent colonies formed. Error bars, S.D.
***P<0.001. D. SRPK3 or MEF2C2 inhibit the size of anchorage independent colonies
formed. The largest colonies observed for each cell line are shown.
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